Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S
Abstract SARS-CoV-2 vaccines BNT162b2, mRNA-1273, and Ad26.COV2.S received emergency use authorization by the U.S. Food and Drug Administration in 2020/2021. Individuals being vaccinated were invited to participate in a prospective longitudinal comparative study of immune responses elicited by the t...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-07-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-022-00504-x |
| _version_ | 1797641808003465216 |
|---|---|
| author | Dominique J. Barbeau Judith M. Martin Emily Carney Emily Dougherty Joshua D. Doyle Terence S. Dermody Alejandro Hoberman John V. Williams Marian G. Michaels John F. Alcorn W. Paul Duprex Anita K. McElroy |
| author_facet | Dominique J. Barbeau Judith M. Martin Emily Carney Emily Dougherty Joshua D. Doyle Terence S. Dermody Alejandro Hoberman John V. Williams Marian G. Michaels John F. Alcorn W. Paul Duprex Anita K. McElroy |
| author_sort | Dominique J. Barbeau |
| collection | DOAJ |
| description | Abstract SARS-CoV-2 vaccines BNT162b2, mRNA-1273, and Ad26.COV2.S received emergency use authorization by the U.S. Food and Drug Administration in 2020/2021. Individuals being vaccinated were invited to participate in a prospective longitudinal comparative study of immune responses elicited by the three vaccines. In this observational cohort study, immune responses were evaluated using a SARS-CoV-2 spike protein receptor-binding domain ELISA, SARS-CoV-2 virus neutralization assays and an IFN- γ ELISPOT assay at various times over six months following initial vaccination. mRNA-based vaccines elicited higher magnitude humoral responses than Ad26.COV2.S; mRNA-1273 elicited the most durable humoral response, and all humoral responses waned over time. Neutralizing antibodies against the Delta variant were of lower magnitude than the wild-type strain for all three vaccines. mRNA-1273 initially elicited the greatest magnitude of T cell response, but this declined by 6 months. Declining immunity over time supports the use of booster dosing, especially in the setting of emerging variants. |
| first_indexed | 2024-03-11T13:51:02Z |
| format | Article |
| id | doaj.art-37e27182c7314a17be809feaa3a678d0 |
| institution | Directory Open Access Journal |
| issn | 2059-0105 |
| language | English |
| last_indexed | 2024-03-11T13:51:02Z |
| publishDate | 2022-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Vaccines |
| spelling | doaj.art-37e27182c7314a17be809feaa3a678d02023-11-02T09:01:52ZengNature Portfolionpj Vaccines2059-01052022-07-01711610.1038/s41541-022-00504-xComparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.SDominique J. Barbeau0Judith M. Martin1Emily Carney2Emily Dougherty3Joshua D. Doyle4Terence S. Dermody5Alejandro Hoberman6John V. Williams7Marian G. Michaels8John F. Alcorn9W. Paul Duprex10Anita K. McElroy11Department of Pediatrics, University of Pittsburgh School of MedicineDepartment of Pediatrics, University of Pittsburgh School of MedicineDepartment of Pediatrics, University of Pittsburgh School of MedicineDepartment of Pediatrics, University of Pittsburgh School of MedicineDepartment of Pediatrics, University of Pittsburgh School of MedicineDepartment of Pediatrics, University of Pittsburgh School of MedicineDepartment of Pediatrics, University of Pittsburgh School of MedicineDepartment of Pediatrics, University of Pittsburgh School of MedicineDepartment of Pediatrics, University of Pittsburgh School of MedicineDepartment of Pediatrics, University of Pittsburgh School of MedicineCenter for Vaccine Research, University of Pittsburgh School of MedicineDepartment of Pediatrics, University of Pittsburgh School of MedicineAbstract SARS-CoV-2 vaccines BNT162b2, mRNA-1273, and Ad26.COV2.S received emergency use authorization by the U.S. Food and Drug Administration in 2020/2021. Individuals being vaccinated were invited to participate in a prospective longitudinal comparative study of immune responses elicited by the three vaccines. In this observational cohort study, immune responses were evaluated using a SARS-CoV-2 spike protein receptor-binding domain ELISA, SARS-CoV-2 virus neutralization assays and an IFN- γ ELISPOT assay at various times over six months following initial vaccination. mRNA-based vaccines elicited higher magnitude humoral responses than Ad26.COV2.S; mRNA-1273 elicited the most durable humoral response, and all humoral responses waned over time. Neutralizing antibodies against the Delta variant were of lower magnitude than the wild-type strain for all three vaccines. mRNA-1273 initially elicited the greatest magnitude of T cell response, but this declined by 6 months. Declining immunity over time supports the use of booster dosing, especially in the setting of emerging variants.https://doi.org/10.1038/s41541-022-00504-x |
| spellingShingle | Dominique J. Barbeau Judith M. Martin Emily Carney Emily Dougherty Joshua D. Doyle Terence S. Dermody Alejandro Hoberman John V. Williams Marian G. Michaels John F. Alcorn W. Paul Duprex Anita K. McElroy Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S npj Vaccines |
| title | Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S |
| title_full | Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S |
| title_fullStr | Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S |
| title_full_unstemmed | Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S |
| title_short | Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S |
| title_sort | comparative analysis of human immune responses following sars cov 2 vaccination with bnt162b2 mrna 1273 or ad26 cov2 s |
| url | https://doi.org/10.1038/s41541-022-00504-x |
| work_keys_str_mv | AT dominiquejbarbeau comparativeanalysisofhumanimmuneresponsesfollowingsarscov2vaccinationwithbnt162b2mrna1273orad26cov2s AT judithmmartin comparativeanalysisofhumanimmuneresponsesfollowingsarscov2vaccinationwithbnt162b2mrna1273orad26cov2s AT emilycarney comparativeanalysisofhumanimmuneresponsesfollowingsarscov2vaccinationwithbnt162b2mrna1273orad26cov2s AT emilydougherty comparativeanalysisofhumanimmuneresponsesfollowingsarscov2vaccinationwithbnt162b2mrna1273orad26cov2s AT joshuaddoyle comparativeanalysisofhumanimmuneresponsesfollowingsarscov2vaccinationwithbnt162b2mrna1273orad26cov2s AT terencesdermody comparativeanalysisofhumanimmuneresponsesfollowingsarscov2vaccinationwithbnt162b2mrna1273orad26cov2s AT alejandrohoberman comparativeanalysisofhumanimmuneresponsesfollowingsarscov2vaccinationwithbnt162b2mrna1273orad26cov2s AT johnvwilliams comparativeanalysisofhumanimmuneresponsesfollowingsarscov2vaccinationwithbnt162b2mrna1273orad26cov2s AT mariangmichaels comparativeanalysisofhumanimmuneresponsesfollowingsarscov2vaccinationwithbnt162b2mrna1273orad26cov2s AT johnfalcorn comparativeanalysisofhumanimmuneresponsesfollowingsarscov2vaccinationwithbnt162b2mrna1273orad26cov2s AT wpaulduprex comparativeanalysisofhumanimmuneresponsesfollowingsarscov2vaccinationwithbnt162b2mrna1273orad26cov2s AT anitakmcelroy comparativeanalysisofhumanimmuneresponsesfollowingsarscov2vaccinationwithbnt162b2mrna1273orad26cov2s |